PCVX - SutroVax Total Debt to Capital

Public company logo of Vaxcyte, Inc. (PCVX)

This chart of Vaxcyte, Inc. (PCVX) share prices on the GURU.Markets platform demonstrates a debt load of 0.04. The business is currently in a pre-commercial investment phase, where market value is driven by clinical trial results rather than economics. The company focuses on developing cutting-edge drugs against pneumococcal infections, relying on grants and external funding due to the absence of recurring sales.

PCVX: Vaxcyte Total Debt to Capital 07/04/2022 - 10/29/2026

Analytical breakdowns for Vaxcyte, Inc.

- price and consensus price forecast:
Price Chart Vaxcyte|PCVX - Forecast Levels Chart
- market capitalization statistics:
Market Capitalization Vaxcyte|PCVX - Value Adjusted for Debt and Cash
- book capitalization indicators:
Book Value per Share Vaxcyte|PCVX - Book Capitalization|Market Value to Book Value Ratio vaxcyte.com|PCVX - Aggregate Asset Value
- company total debt and liquidity indicators:
Debt to Equity Vaxcyte, Inc.|PCVX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Vaxcyte, Inc.|PCVX - Company Aggregate Debts|Debt to Book Value Vaxcyte|PCVX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Vaxcyte
Basic company analysis:Vaxcyte
Core merchandise of SutroVax

This indicator is calculated as the sum of all debt obligations divided by the amount of equity, allowing for an assessment of financial leverage and bankruptcy risk. For Vaxcyte, Inc. (PCVX), which is challenging pharma behemoths, the total debt-to-equity ratio reflects the balance between the aggressive scaling of scientific research and the maintenance of the business's financial stability.

Competitor analysis for Vaxcyte, Inc.

Debt to Equity Summit Therapeutics Inc.|Moderna Inc - Aggregate Debt to Equity|Total Debt to Capital TARS|CRMD (CorMedix Therapeutics) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital MCRB (Seres Therapeutics)|Total Debt to Capital sperotherapeutics.com SPRO|SCYX - Debt to Equity|All Debt to Shareholders' Equity Ratio ANTX (AN2 Therapeutics, Inc.)|polypid.com (PYPD) - Debt to Equity|Total Debt to Equity Ratio YS Biopharma Co., Ltd.|ITRM (Iterum Therapeutics PLC) - Total Debt to Capital|Total Debt to Capital BiomX Ltd|Total Debt to Equity Ratio SNGX (Soligenix, Inc.)|SXTP (60degreespharma.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital OGEN (Oragenics)|Total Debt to Capital Coefficient Onconetix Corporation (ONCO)|OPGN - Debt to Equity